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Abstract 
Dietary intervention with ω-3 marine fatty acids may potentially modulate inflammation 
and oxidative stress markers related with CVD, metabolic syndrome, and cancer. The 
aim of this study was to evaluate whether different proportions of ω-3 EPA and DHA 
intake provoke a modulation of the production of lipid mediators and then, an influence 
on different indexes of inflammation and oxidative stress in a controlled dietary animal 
experiment using Wistar rats. For such scope, a lipidomic SPE-LC-ESI-MS/MS 
approach previously developed was applied to determine lipid mediators profile in 
plasma samples. The effect of ω-3 fatty acids associated to different ratios EPA:DHA 
was compared with the effect exerted by ω-3 ALA supplementation from linseed oil and 
ω-6 LA from soybean oil. CRP showed a tendency to greater inflammatory status in all 
ω-3 fed animals. Interestingly, ratios 1:1 and 2:1 EPA:DHA evidenced a noteworthy 
healthy effect generating a less oxidative environment and modulating LOX and COX 
activities towards a decrease in the production of pro-inflammatory ARA eicosanoids 
and oxidative stress biomarkers from EPA and DHA. In addition, the ability of 1:1 and 
2:1 fish oil diets to reduce lipid mediator levels was in concurrence with the protective 
effect exerted by decreasing inflammatory markers as ω-6/ω-3 ratio in plasma and 
membranes. It was also highlighted the effect of a higher DHA amount in the diet 
reducing the healthy benefits described in terms of inflammation and oxidative stress. 
Results support the anti-inflammatory and anti-oxidative role of fish oils, and 
particularly the effect of adequate proportions EPA:DHA. 
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1. Introduction 
 
Oxidative stress is known to trigger oxidative damage of cellular biomolecules (i.e., 
lipids, proteins, DNA) and has been linked to the development of inflammation and 
metabolic diseases [1]. Moreover, exhaustion or lack of activation of necessary 
inflammatory resolution mechanisms could result in subsequent organ damage, obesity, 
metabolic syndrome, diabetes, CVD or even cancer [2,3]. Anti-inflammatory and pro-
inflammatory targets can alter hormonal signaling cascades to the modulation of innate 
immune system, via toll-like receptors and gene transcription factors resulting in the 
inhibition or activation of inflammatory pathways [2]. Accordingly, one of the most 
selective markers of cellular inflammation is the blood ratio ω-6/ω-3, the higher ratio 
the greater pro-inflammatory conditions [4]. In addition, fatty acid desaturases (FAD) 
are important regulators of the endogenous metabolism of ω-6 and ω-3 PUFAs, and also 
regulate the desaturation of SFAs to corresponding MUFAs. High FADs activity related 
with the formation of oleic, palmitoleic, and arachidonic acids has been associated with 
obesity, hypertriacylglycerolemia, metabolic syndrome, and the risk of developing 
insulin resistance. In contrast, FADs associated with ω-3 EPA and DHA pathways 
indicate insulin sensitivity, and the decrease of metabolic syndrome and CVD [5]. 
 
Moreover, ω-6 and ω-3 PUFAs are the main substrate of COXs, LOXs and CYP450 
which produce a wide range of oxygenated lipid mediators that have been suggested as 
signaling molecules that may influence inflammation in a highly coordinated active 
process [6,7]. Specific examples include ARA eicosanoids (PGs, TXs, and LTs) [6] and 
IsoPs [8] which have been suggested as strong pro-inflammatory substances. The most 
studied: PGE2, PGF1α, PGF2α, TXA2 and 8isoPGF2α, have been associated with 
inflammatory stages in studies related to hypercholesterolemia, liver cirrhosis, 
myocardial reperfusion, type-2 diabetes, obesity, atherosclerosis, cancer, and CVD 
[2,3,9,10]. On the other hand, many EPA and DHA derivatives have been suggested as 
signaling molecules and less harmful compounds than the corresponding ω-6 
metabolites [11,12]. Finally, the strong anti-inflammatory and cellular protective 
activity of EPA and DHA resolvins and protectins has been described in studies related 
to CVD, dry eyes or Alzheimer [13,14]. The formation cascade of ARA, EPA and DHA 
metabolites is shown in the Fig. 1. 
 
Dietary interventions have shown to modulate the specific markers of cellular 
inflammation and oxidative stress. Regular consumption of marine ω-3 PUFAs, 
principally EPA and DHA, has been associated with the reduction of CVD risk factors 
like plasma TG, LDL, and platelet aggregation, and with the improvement of 
endothelial functions, and prevention of inflammatory pathways [15]. Brahmbhatt et al. 
have found protective effects over the intestinal inflammation of rats fed EPA:DHA 
(3:2) diet. The reduction of the intestinal injury was associated with the decline of 
oxidative stress, the up-regulation of 8isoPGF3α (anti-inflammatory marker derived 
from EPA), and down-regulation of ARA pro-inflammatory metabolites (i.e. PGE2, 
LTB4, PGD2, Trioxilin A3 and B3) [16]. In a similar way, McDaniel et al. have 
suggested that EPA:DHA (1.3:1) supplements may alter inflammation indexes in human 
plasma and blister fluids. They found a decrease of ω-6/ω-3 ratio and ARA pro-
inflammatory metabolites (i.e., LTB4, 15HETE, TXB2) in a microenvironment of acute 
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human wounds; meanwhile an increase of EPA anti-inflammatory derivates (i.e., 5-12-
15HEPE, PGD3, PGE3, TXB3) and 18HEPE, precursor of anti-inflammatory RvE1 [17]. 
Similar results have been achieved by Neilson et al. in dietary experiments in rats [18]. 
 
This investigation was aimed to delve deeper into the potential anti-inflammatory and 
anti-oxidant effects of ω-3 marine fatty acids in a controlled fed animal experiment in 
Wistar rats. Despite the growing evidence of health benefits associated to marine ω-3 
lipids, there is no agreement about a recommended daily intake in the form of DHA and 
EPA [19]. Therefore, we evaluated the influence that marine oils having different 
proportions of EPA and DHA exerted on different lipid biomarkers of oxidative stress 
and inflammation. Wistar female rats were fed standard diets enriched with fish oil 
containing three different EPA:DHA ratios (1:1, 2:1, and 1:2), and were compared with 
animals fed soybean and linseed oils. Soybean oil is a rich source of the ω-6 LA, the 
dietary precursor of ARA biosynthesis; whereas, linseed oil has an elevated content of 
ω-3 ALA, which slightly derives to EPA and DHA. The synthesis of ω-3 and ω-6 
eicosanoid and docosanoids, the regulation of plasma and membrane FA composition, 
and the FADs activity were correlated with biochemical measurements and parameters 
of oxidative stress and inflammation (i.e. ORAC, antioxidant enzymes activity, CRP 
and protein carbonylation level in plasma, kidney, muscle, and liver). 
 
2. Materials and Methods 
 
2.1. Animals and diets 
Thirteen-week old female Wistar (n=35, Janvier, France) rats were used as animal 
models. Body weight was recorded on arrival and weekly thereafter (data not shown). 
All the specimens were kept in an isolated room with a constantly regulated temperature 
an controlled humidity (222 oC, 5010 % humidity) on a 12h light/dark cycle with ad 
libitum access to water and standard pelleted A04 chow for rodents (16% protein, 60% 
carbohydrate, 3% fat, 4% fiber and 5% ash; Harlan Iberica, Barcelona, Spain). Animals 
were randomized in five dietary groups: soybean (n=7), linseed (n=7), EPA:DHA 1:1 
(n=7), EPA:DHA 2:1 (n=7), and EPA:DHA 1:2 group (n=7). Each group was feed with 
a single weekly dose of 0,8 ml/kg of the assigned oil supplement as listed in 
Supplementary Material S1. Oil supplements were prepared as previously described 
[20]. All diets had a similar fat and energy content. The molar percentage of SFA, 
MUFA and PUFA was kept constant. Nonetheless, they significantly differed in the 
proportion of individual fatty acids. Because PUFA are easily oxidized and the 
oxidation products are potentially toxic, the peroxide value of the oils administered was 
checked periodically by the ferric thyocianate method [21]. It was below 5 meq O2/Kg 
of oil throughout the interventional study. After a 2-week adaptation period, the oils 
were administrated for 13 weeks and the experiment ended when the rats were 28 weeks 
old. Then, the rats were fasted overnight, anesthetized and killed by exsanguinations. 
Handling and killing of the animals were in full accordance with the European Union 
guidelines for the care and management of laboratory animals and the pertinent 
permission was obtained from the CSIC Subcommittee of Bioethical Issues (ref. 
AGL2009-12 374-C03-03). 
 
2.2. Fatty acid analysis of the oil supplements 
To determine the fatty acid composition of the oil supplements, 0.6 mg of lipid were 
methylated according to Lepage and Roy [22]. The fatty acid nonadecanoic acid was 
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used as an internal standard. The FAMEs were analyzed by gas chromatography GC-
FID. Results are shown in Supplementary Material S1. 
 
2.3. Plasma and erythrocyte sampling for FA analysis 
Blood samples were collected via cardiac puncture into polypropylene tubes containing 
EDTA (1 mg/ml) to remove erythrocytes, and centrifuged for 15 min, at 4 oC and 850 g. 
After that, the buffy coat was removed and the packed erythrocyte cells were washed 
according to the protocol developed by Sonenberg [23]. Erythrocytes were collected 
into clean polypropylene tubes, frozen and kept at -80 oC until required. Then, 
erythrocyte free plasma was supplemented with 5 mM PMSF (protease inhibitor) and 
samples were immediately stored at -80 ºC until required. 
 
2.4. Extraction and analysis of plasma TFA and FFA 
Plasma samples for the analysis of TFA (30 µL) and FFA (100 µL) were first spiked 
with an internal standard of nonadecanoic acid (Larodan Fine Chemicals, Malmö-
Sweden), and then, extracted with a dichloromethane:methanol:water mixture (2:2:1, 
v/v) according to Bligh and Dyer [24]. TFA were directly analyzed in the organic phase 
after dryness under a stream of nitrogen gas. Then, samples were transesterified and 
analyzed by gas chromatography (GC-FID, Clarus 500, Perkin–Elmer) following the 
method of Lepage and Roy [22]. To isolate the FFA fraction, the resulting lipid mixture 
obtained from the Bligh and Dyer extraction was subjected to SPE on aminopropyl 
cartridges (500mg, 6mL, Biotage, Uppsala-Sweeden) as Kaluzny et al. described [25]. 
The solvent was removed under a stream of nitrogen and then subjected to 
transesterification and GC-FID analysis. Results are shown in Tab. 1. 
 
2.5. Extraction and analysis of FA from erythrocyte membranes 
To study the profile of FA from the erythrocyte membranes, lyophilized erythrocyte 
samples (50 mg) were extracted with the Bligh and Dyer modified procedure [26]. The 
organic layer was dried under nitrogen and the lipid content was gravimetrically 
quantified. Finally, an aliquot of organic phase containing 0.15 mg of lipids was dried, 
the internal standard was spiked and transesterification and GC analysis were done as 
before indicated to plasma FA (Tab. 1). 
 
2.6. Fatty acid desaturase (FAD) indexes measurement 
Desaturase activities of dietary supplemented groups were measured using a validated 
methodology from the TFA data [27]. FAD indexes were calculated as 
product/precursor ratio for: SCD (SCD-16 or SCD-18) = [palmitoleic (16:1 ω-
7)/palmitic (16:0)] or [oleic (18:1 ω-9)/stearic (18:0)]; 5D = [ARA (20:4 ω-6)/DGLA 
(20:3 ω-6)] and [DHA (22:6 ω-3)/DPA (22:5 ω-3)]; 6D = [DGLA (20:3 ω-6)/LA (18:2 
ω-6)]; and 5/6D = [EPA (20:5 ω-3)/ALA (18:3 ω-3)]. Results are shown in Tab. 2. 
 
2.7. Solid-phase Extraction method for lipid metabolites isolation from plasma samples 
ARA, EPA and DHA oxidized lipid mediators were extracted from plasma samples by 
SPE following the method previously developed [28]. Briefly, samples (90 µL) were 
diluted with 30% cold methanol (v/v), to a final volume of 1 mL and spiked with the 
internal standard 11HETE-d8. After centrifugation (1800g, 10 min, 4º C), samples were 
loaded into conditioned Oasis-HLB cartridges (60mg, 3mL, Waters, MA-USA). Then, 
cartridges were washed with 5mL 15% methanol (v/v), 5 mL Milli-Q water and 2.5 mL 
hexane in succession. After sorbent dryness, analytes were eluted with 2 mL methyl 
formate. Extracts were evaporated to dryness, re-dissolved in 30 µL ethanol, and 
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analyzed by LC-ESI-MS/MS. Standard solutions of lipid mediators were purchased 
from Cayman Chemicals (Ann Arbor, MI, USA). Methanol and Water, Optima LC-MS, 
were purchased from Fisher Scientific (New Jersey, USA). 
 
2.8. Analysis of lipid metabolites by LC-ESI-MS/MS 
Lipid mediators were quantified according to the methodology previously developed 
[28] and results are shown in Tab. 3. Briefly, analyses of SPE extracts were carried out 
on an Agilent 1260 Series (Agilent, Palo Alto, CA) coupled to a linear ion trap mass 
spectrometer LTQ Velos Pro with ESI (Thermo Fisher, Rockford, IL, USA). A Waters 
C18-Symmetry column, 150×2.1 mm, 3.5 μm (Milford, MA, USA) protected with a 
4×2 mm C18 guard cartridge provided by Phenomenex (Torrance, CA, USA) was used. 
A binary eluent system of water (A) and methanol (B), both with 0.02% (v/v) of formic 
acid, was used as mobile phase. The injection volume was set to 10 μL, ESI source 
operated in negative ion mode, and MS/MS conditions has been reported in detail 
elsewhere [28]. The quantification of target compounds was made using the most 
intense, or selective, ion in their product ion scan MS/MS spectra. Retention times for 
target compounds and individual MS/MS parameters are summarized in Supplementary 
Material S2. 
 
2.9. Statistical analysis 
Data presented are expressed as mean ± SD. Statistical analyses were performed by one-
way analysis of variance (ANOVA) with R free software (version 386 3.1.0). The 
means were further compared by the post-hoc test Fisher least square difference (Fisher 
LSD) and significant differences were set at p<0.05. Pearson test was used in order to 
determine the statistical correlation between compounds and PUFAs intake. 
 
3. Results  
 
The effect of dietary interventions on eicosanoid and docosanoids synthesis, plasma and 
membrane fatty acid composition, and desaturases activity is described. Data obtained 
were correlated with previous parameters determined in the same animals and 
summarized in Tab. 2 [20,29]. In detail, different CVD related parameters were 
measured: TFA, TG, TC, HDL, LDL, HbA1c. General inflammation was measured by 
the concentration of CRP. Oxidative stress of animals was determined through the 
plasma antioxidant capacity, activity of major erythrocyte antioxidant enzymes (SOD, 
CAT, GPX), and by carbonylation of proteins of liver, muscle, kidney and plasma. 
 
3.1. Effect of dietary interventions on plasma FFA profile, and FA incorporation into 
tissues. Ratio ω-6/ω-3. 
It has been observed that animals fed with enriched ω-3 PUFAs (fish and linseed oils) 
exhibited significant higher levels of plasma ω-3 FFA compared to those fed with the 
control ω-6 soybean diet. Meanwhile, the content in plasma ω-6 FFA was not modified 
by dietary intervention; therefore, the ratio ω-6/ω-3 became lower with all ω-3 
supplements and higher by soybean treatment (Tab. 1). In addition, it is important to 
highlight the different fatty acid species that contributed to this ω-3 enhancement. The 
content of EPA and DHA increased in the three fish oil diets (without significant 
differences between them) when compared with soybean group. Whereas, animals fed 
linseed diet enhanced the content of ω-3 ALA when compared with soybean animals. 
Data were in agreement with the elevated content of EPA and DHA in fish supplements, 
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while ALA was the main ω-3 fatty acid in the linseed diet. The profile level of 
individual PUFAs showed the same tendency between the five groups: LA >> ARA > 
DHA > ALA > EPA (Supplementary Material S3). 
 
The PUFAs incorporation from dietary intake into tissues is reflected in the erythrocyte 
membrane fatty acid composition [30]. Experimental groups under fish oil 
supplementation showed a significant enrichment of EPA, DPA, and DHA in the 
membranes, and thus, they increased the total ω-3 composition when compared with 
control ω-6 and ω-3 linseed group. Moreover, fish diets revealed the lowest ARA 
incorporation and lowest total ω-6 levels into tissues. Therefore, the inflammatory index 
ω-6/ω-3 was significantly reduced by fish oil diets (without differences between 1:1, 2:1 
and 1:2 groups) in comparison with linseed and soybean treatments. In addition, 
modulation of PUFA ratios in erythrocyte membrane by linseed supplementation was 
more moderated than fish diets. EPA and DPA also exhibited a significant enrichment by 
linseed supplementation when compared with soybean group, whereas DHA was poorly 
incorporated in linseed diet and it remained in the same level as soybean fed animals, 
significantly lower than fish ones. The ARA content was slightly reduced by linseed 
diet, and interestingly, the main -3 PUFA of linseed supplement, ALA, was not 
significantly incorporated into the erythrocyte membranes. As a consequence, the ω-
6/ω-3 ratio of linseed fed animals showed a highest value compared with fish oil 
groups. Results are shown in Tab. 1, and the comparison of the FA erythrocyte 
membrane profiles between the five groups is shown in the Supplementary Material S4: 
ARA >> LA > DHA > EPA > ALA. 
 
3.2. Effect of dietary interventions on FAD activity 
Results outlined that the studied supplements did not exert a different influence on 
SCD-16 [palmitoleic/palmitic], SCD-18 [oleic/stearic] and 6D [DGLA/LA] activities. 
Nevertheless, ω-3 intake from fish and linseed diets was effective in down regulating 
5D-(ARA/DGLA) activity when compared with soybean diet. Results highlighted the 
ability of fish EPA and DHA intake in harnessing D [EPA/ALA] and 5D 
[DHA/DPA] activities in comparison with linseed and soybean groups. No differences 
were found between diets with different EPA:DHA ratios (Tab. 2). 
 
3.3. Determination of lipid mediators in plasma depending on the ingested amount of 
ARA, EPA and DHA 
Plasma collected from dietary groups was analyzed to determine a wide range of lipid 
mediators from the family of prostaglandins, leukotrienes, thromboxanes, isoprostanes, 
resolvins, protectins, hydroxy and hydroperoxy acids. The correlation between the 
weekly dose of ARA, EPA and DHA given to rats and the further production of 
eicosanoids and docosanoids was also statistically analyzed. 
 
Several hydroxy and hydroperoxy derivates, thromboxane and prostaglandin 
metabolites from ARA, EPA and DHA have been identified and levels are shown in 
Tab. 3. In detail, five EPA eicosanoids from the family of hydroxides (15HEPE and 
12HEPE), hydroperoxides (15HpEPE and 12HpEPE), and a thromboxane (TXB3) have 
been identified. From DHA, the 17HDoHE (hydroxide) and 17HpDoHE 
(hydroperoxide) were identified. Finally, a hydroxide and a prostaglandin derived from 
ARA, 11HETE and PGE2 respectively, have also been found in plasma samples from 
dietary interventions. After quantification and statistic comparison between groups, data 
revealed that dietary interventions with 1:1 and 2:1 EPA:DHA fish oils generally 
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decreased levels of lipid mediators when compared with 1:2 fish oil, linseed and 
soybean groups. 
 
The general comparison between dietary groups showed that levels of hydroxides and 
hydroperoxides from EPA and DHA were lower by 1:1 and 2:1 fish diets, while higher 
by 1:2 fish, linseed and soybean treatments. A similar trend was observed for ARA 
strong-inflammatory derivates. According to precursor PUFAs, they followed an 
opposite tendency in comparison with their derivates: ARA, EPA and DHA levels were 
higher in 1:1 and 2:1 animals. Particularly, TXB3 was only observed in linseed group 
and isoprostanes, leukotrienes, resolvins, and protectins were not detected. Interestingly, 
these results suggest that dietary 1:1 and 2:1 fish oil interventions were the best 
EPA:DHA proportions in order to reduce the production of lipid derived hydroxides and 
hydroperoxides and further strong pro-inflammatory substances. 
 
In detail, levels of 15 and 12HEPEs (EPA hydroxides) significantly increased in linseed 
diets compared with soybean, 1:1, and 2:1 groups. Animals fed with 1:2 fish diet 
produced similar average levels as linseed group, but not statistically different when 
compared with other diets. In addition levels of 15 and 12HpEPE (EPA hydroperoxides) 
decreased in 1:1 and 2:1 fish oil supplementations compared with 1:2 and linseed 
groups, while soybean diet produced intermediate levels. A similar pattern was found 
for docosanoids derived from DHA: the level of 17HpDoHE was found to be higher in 
1:2, soybean and linseed groups and lower in 1:1 fish diet; and the level of 17HDoHE 
significantly increased in linseed group compared with 1:1, 2:1 and soybean diets. 
Levels of 17HDoHE produced in 1:2 diet were similar to linseed one, but not 
statistically different when compared with other diets.  
 
Moreover, the strong pro-inflammatory lipid mediators derived from ARA, 11HETE 
and PGE2, were significantly less-produced by dietary 1:1 and 2:1 interventions while 
linseed diet produced the highest concentrations for these compounds. Control soybean 
diet showed intermediate values but significantly higher than 1:1 fish oil treatment for 
11HETE. Diet 1:2 produced similar values as linseed one, higher than other diets but 
not statistically different.  
 
In addition, the analysis of the ω-3 precursors, EPA and DHA, showed the highest 
levels by 1:1 and 2:1 fish diets when compared with 1:2, linseed and soybean groups. 
Accordingly, the level of ω-6 ARA showed the same tendency as EPA and DHA, 
although only the comparison between 2:1, 1:2 and linseed groups was statistically 
different. 
 
Finally, TXB3 was found in all animals (n=7) fed with linseed supplement but it was 
barely identified in the rest of the groups (n=1-3). Other searched compounds as 
5HEPE, 8iso-PGF3α, 8iso-PGF2α, PGD3, PGE3, 11HDoHE, 4HDoHE, RvD1, PDx, and 
LTB4 were not produced by any of the diets or were under the detection limits of the 
method. 
 
Interestingly, the correlation analysis between the levels of lipid mediators in plasma 
and the dietary intakes of EPA and DHA, showed that the intake of 20C fatty acids 
(EPA and ARA) exerted a different effect over the production of metabolites when 
compared with 22C DHA. In detail, an increase in the ingested amount of EPA or ARA 
produced an enhancement in plasma levels of ARA, EPA and DHA (positive correlation 
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indexes over 88-97%), however it produced a decrease in hydroperoxide levels (primary 
oxidation products) with negative correlation indexes over 87-96%, and a tendency was 
observed towards the decrease of secondary metabolites production (hydroxides, 
prostaglandins), but not statistically correlated. On the other hand, an increase in the 
ingested amount of DHA was weakly correlated with a higher level of ARA, EPA and 
DHA in plasma and a lower level of hydroperoxides. Moreover, DHA intake produced 
an inversion in the tendency of secondary metabolites production compared with EPA 
and ARA intakes towards an enhancement. Calculated Pearson indexes are shown in 
Tab. 4. Therefore, results suggested a decrease of the oxidation of ARA, EPA, and 
DHA and thus, a minor production of their metabolites when the dietary intake of EPA 
is higher; meanwhile, the increase of DHA in the diet reduced this antioxidant effect 
and even enhanced the production of secondary oxidative metabolites. Interestingly, 
these findings are in agreement with the stronger antioxidant effect exerted by 1:1 
EPA:DHA and 2:1 EPA:DHA diets when compared with 1:2 EPA:DHA as it was 
previously described [20].  
 
4. Discussion 
 
Data of this study bring evidence that the consumption of EPA/DHA provokes a more 
anti-inflammatory than pro-inflammtory effect in animals fed with standard diets. In 
particular, fish oil supplements with 1:1 and 2:1 EPA:DHA proportions demonstrated to 
be the most effective treatments to produce an anti-inflammatory response compared 
with 1:2 EPA:DHA, linseed and soybean supplements. Such affirmation is based on the 
identification and quantitation of several lipid local mediators. In detail, ARA ω-6 
eicosanoids like PGE2 and 11HETE, have been widely studied and identified as a key 
pro-inflammatory signaling molecules related with pro-aggregating, vasoconstrictive 
and immunosuppressive processes [9]; and they have also been associated with 
promotion of different human cancers including colon, lung, breast, head or neck [3]. 
On the other hand, derived eicosanoid and docosanoids from EPA and DHA have been 
related with protective effects on inflammation diseases [16], the regulation of tumor 
factors [18], or the reduction of CVD risk [10]. However, hydroxides and 
hydroperoxides derived from EPA and DHA were also considered as biomarkers of 
oxidative stress and weaker inflammatory substances than the corresponding ARA 
derivates [2,31]. In the same way, TXB3 derived from EPA is related with the 
inflammatory response, and a weaker pro-inflammatory product than corresponding 
series-2 thromboxanes from ARA [17]. 
 
One of the mechanisms by which EPA and DHA are thought to act is through substrate 
competition with ARA for enzymes that generate several inflammatory mediators 
[2,10]. As a consequence, when increasing amounts of ω-3 substrate are included in the 
diet, LOXs and COXs would preferably regulate the production of ω-3 derivates instead 
of ω-6 ones. Therefore, strong-inflammation targets derived from ω-6 PUFAs would be 
less produced and replaced by less harmful ω-3 eicosanoids. Accordingly, it was 
observed a significant reduction of related pro-inflammatory ω-6 eicosanoids after 1:1 
and 2:1 diets compared with other groups; although levels of searched ω-3 were not 
equally enhanced. On the other hand, 1:2 diet showed similar results as soybean (source 
of ω-6 LA), and linseed (source of ω-3 ALA). Therefore, not only a substrate 
competition for LOX and COX but other mechanisms may be implicated in the minor 
anti-inflammatory response observed in 1:2, linseed and soybean fed animals. 
 
 9
It is known that LOXs regulate the synthesis of hydroperoxides (HpEPEs and 
HpDoHEs), which are further reduced into hydroxides (HEPEs and HDoHEs) through 
GPX activity. In addition, COXs regulate the synthesis of strong pro-inflammatory ω-6 
eicosanoids like 11HETE and PGE2, and less harmful ω-3 ones like TXB3 [6]. Soybean, 
linseed and 1:2 groups showed significant lower GPX activities and higher 
hydroperoxides levels than 1:1 and 2:1 ones. Therefore, the down-regulation of GPX in 
soybean, linseed and 1:2 groups may be correlated with a decrease of hydroperoxides 
detoxification and consequently, with the highest values found for 12HpEPE, 
15HpEPE, and 17HpDoHE. Moreover, a decrease of LOX activity after 1:1 and 2:1 
interventions could explain the lowest hydroxide levels found in these diets despite the 
higher GPX activity observed. A similar trend was observed for COX products: 
soybean, linseed and 1:2 groups showed higher values than 1:1 and 2:1 ones. 
Specifically, TXB3 was preferably found after linseed treatments; and thus, it seemed 
that this diet had a direct influence on the pathway of this eicosanoid. In concordance 
with these findings, the statistical correlation analysis between weekly dose of EPA and 
DHA in the diet and the production of lipid metabolites showed that the increase of 
DHA amount in the diet lead to higher eicosanoid and docosanoids production. 
Meanwhile, the increase of EPA amount in the diet lead to lower metabolites production 
as it was observed when 1:2 EPA:DHA supplement was compared with 2:1 one. 
Therefore, in addition to the substrate competition for LOXs and COXs, it seemed that 
specific PUFAs profile of the diet may modulate enzymes activity towards different 
eicosanoid and docosanoids production. 
 
In addition, not only enzymatic pathways but free radical oxidation mechanisms 
initiated by ROS also lead to the formation of described eicosanoid and docosanoids 
[32]. Accordingly, the susceptibility of fatty acids to oxidation is thought to be directly 
dependent on their degree of unsaturation, and subsequently, supplementations with 
highly unsaturated ω-3 PUFA have been reported to increase oxidative damage [30]. 
Therefore, the higher unsaturation level of DHA may increase the susceptibility of the 
molecule to be oxidized compared to EPA, rending to a higher level of free radicals. 
Then, the supplement with higher DHA proportion (1:2) would produce a higher 
concentration of ROS and be more prone to suffer free radical oxidation processes than 
supplements with higher EPA or balanced ratios.  
 
Richard et al. investigated the free radical-scavenging potential of ω-3 and ω-6 
supplements in cell cultures studies [33]. They observed that supplemented cells with ω-
3 PUFAs produced lower amounts of ROS than cells fed with ω-6 ARA and LA despite 
the lower unsaturation level of the molecules. It was shown that ω-6 series were more 
susceptible to oxidize than ω-3 ones. Therefore, it was suggested that the susceptibility 
to oxidation of PUFA molecules is not as straightforward as hypothesized. Not only the 
lower degree of unsaturation leads to higher antioxidant activity, but the chemical 
structure may play an important role in the different antioxidant aptitude. Regarding to 
our results, ω-3 ALA from linseed and ω-6 LA from soybean seemed to be easier 
oxidized than ω-3 EPA and DHA in mixtures 1:1 and 2:1, but the same results were 
found when compared with 1:2 mixture. In addition, the higher oxidizability suggested 
for soybean, linseed and 1:2 supplements was in concurrence with the lower PUFA 
levels found in plasma. Accordingly, PUFAs would be oxidized into the corresponding 
eicosanoid and docosanoids due to free radical reactions and enzymes pathways. The 
opposite trend was achieved for 1:1 and 2:1 where PUFA levels were higher and lipid 
derivates lower than the other diets. Other studies have also described the activation of 
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the antioxidant response after ω-3 EPA and DHA supplementation: enhance of SOD 
[34], and CAT activities [35], and genes related to endogenous antioxidant system [36]; 
although the different aptitude of EPA vs DHA have not been described yet. 
 
As a conclusion for eicosanoid and docosanoids profiles, 1:1 and 2:1 interventions were 
the most effective treatments to reduce the synthesis of inflammatory lipid mediators. 
Different mechanisms were thought to modulate the activity of crucial enzymes 
involved in the generation of these compounds. In detail, it was suggested a competition 
for the same enzymes between substrates, and the different oxidizability between 
PUFAs due to their chemical structure and unsaturation degree. As a result, enriched 
diets with ALA, LA or 1:2 EPA:DHA exhibited lower anti-oxidative and anti-
inflammatory properties than 1:1 and 2:1 EPA:DHA. 
 
In addition to the lipidomic analysis, the influence of dietary supplements on metabolic 
parameters like FAD, and FFA in plasma and tissues was measured. Results were 
finally correlated with previous data about inflammation, biochemical measurements, 
and oxidative stress. Fatty acid desaturases are one of the main targets for the treatment 
of metabolic related disorders, and the rate-limiting step in the biosynthesis of different 
PUFAs [5]. According to their activities, diets enriched with ω-3 PUFAs from fish and 
linseed provoked a down-regulation of FAD involved in the transformation of LA into 
ARA. Therefore, intervention on the diet with ω-3 PUFAs seemed to reduce ω-6 ARA 
levels, the main substrate of pro-inflammatory ω-6 eicosanoids. Interestingly, the high 
intake of ALA due to linseed diet did not address an increase of FADs activity involved 
in the synthesis of EPA and DHA from ALA. This finding is in agreement with Fu et al. 
who demonstrated ALA to be more prone to β-oxidation or excretion rather than 
elongate to EPA and DHA [37]. Our results suggested that linseed supplements were 
not effective to potentiate EPA and DHA endogenous synthesis. Therefore, some 
benefits directly attributed to fish PUFAs like production of specific anti-inflammatory 
metabolites could not be obtained by vegetal ω-3 supplements. 
 
A huge number of lipid species in plasma are triacylglycerol, glycerophospholipids and 
cholesterol esters. Increasing levels of these substances have been associated with 
chronic inflammation and CVD conditions [38]. In addition, a small fraction of total 
lipids, the FFA released from adipose tissue; are thought to exert relevant functions as 
signaling molecules participating in inflammation processes and oxidative stress [39]. 
Results showed that ω-6 PUFA levels in plasma remained unaltered with the different 
dietary interventions; however, ω-3 EPA and DHA increased after fish oil diets and ω-3 
ALA after linseed one as expected. The capacity of fish oil interventions to enrich the 
plasma FFA in DHA and EPA, and the anti-inflammatory effect attributed was already 
investigated [40]. As a consequence, animals fed with fish and linseed oils exhibited 
significantly lower ω-6/ω-3 plasma ratios than the soybean group. It has been reported 
that the higher ω-6/ω-3 ratio the greater pro-inflammatory conditions [4,17]. 
Furthermore, fish supplements were also effective to increase EPA and DHA 
incorporation into erythrocyte membranes, meanwhile ARA incorporation was reduced. 
Results were in agreement with those obtained by Massaro et al. [10]. Therefore, ω-6/ω-
3 ratios in tissues were also reduced due to fish oil diets. Nevertheless, although linseed 
fed animals showed similar ω-6/ω-3 plasma ratios than fish groups, linseed diet was not 
effective to incorporate ALA into tissues. And thus, membrane ω-6/ω-3 ratios showed 
lower values than obtained after fish oils. 
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The decrease of the inflammation index ω-6/ω-3 due to ω-3 supplements was in 
concordance with the tendency to decrease CRP marker under fish and linseed diets 
observed in previous studies in the same animals [29]. Lower values of CRP indicate a 
reduction in general inflammation conditions linked to CVD [41]. Although CRP is 
regarded a potential inflammatory index, additional biomarkers like IL-6, IL-1 or TNFα 
would be desirable to strongly conclude the differences in the inflammatory status of 
dietary groups [42]. In any case, the general anti-inflammatory effect described by 
lipidomic and CRP data after ω-3 fish diets may be also correlated with the general 
decrease observed in other parameters like TFA, TG, TC, LDL, and HbA1c when 
compared with soybean group [29]. Results for EPA:DHA interventions are in 
agreement with other studies that have suggested a protective role of fish PUFAs, 
essentially by improving the lipid profile and cardiovascular indexes [43], and with 
Reinders et al. who reported CRP levels to be inversely correlated to circulating ω-3 
PUFA concentrations [44]. To finish, the ability of fish diets to ameliorate general 
inflammatory conditions, specially 1:1 and 2:1 EPA:DHA, was in agreement with the 
effectiveness to reduce ROS concentration (higher ORAC), enhance the antioxidant 
endogenous system (SOD, and CAT), and reduce the oxidative damage in proteins 
[20,29]. The general decrease of oxidative stress and inflammatory markers may be 
correlated with the lower production of eicosanoid and docosanoids after 1:1 and 2:1 
supplements as it was discussed above. 
 
5. Conclusion 
 
The investigation shed light on how PUFA composition of the diet may influence the 
synthesis of eicosanoid and docosanoids, and evidenced that 1:1 and 2:1 EPA:DHA 
supplements were the most effective treatments to reduce inflammation and oxidative 
stress when compared with 1:2 EPA:DHA, linseed and soybean ones. It was suggested a 
higher anti-oxidant and anti-inflammatory capacity of EPA vs DHA, and fish ω-3 vs 
vegetal ω-3 and ω-6 PUFAs. It was also studied the influence of ω-6 and ω-3 
supplements in FADs and thus, in the composition and ω-6/ω-3 ratios in plasma and 
tissues. Results suggested greater anti-inflammatory conditions generated after ω-3 
interventions. These findings were in agreement with previous results that had shown 
the effect of 1:1 and 2:1 diets ameliorating inflammation and activating the antioxidant 
response of the organism. Therefore, this research evidenced that in addition to an 
adequate dietary proportion between ω-6 and ω-3 PUFA, the proportion between marine 
ω-3 type lipids is also important and its intake could contribute towards the prevention 
of chronic inflammation and oxidative stress processes that have been correlated with 
metabolic syndrome, CVD, obesity, diabetes or even cancer [2,3]. Previous studies also 
supported the evidence of the protective effect of EPA and DHA intakes [16,31]. 
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Tab. 1: Plasma composition of FFA and FA of erythrocyte membranes (EM) from 
Wistar rats supplemented with different fish oils diets (EPA:DHA 1:1, 2:1 and 1:2), 
linseed oil or soybean oil. Results are expressed as percentage of total fatty acids 
(mg/100mg). Values are shown as means ± SD. Values with different superscript letters 
in the same row indicate significant difference at p < 0.05 between dietary groups. 16:0 
(palmitic acid), 16:1 ω7 (palmitoleic acid, PA), 18:0 (stearic acid), 18:1 ω9 (oleic acid, 
OA), 18:1 ω7 (vaccenic acid), 18:2 ω6 (LA), 18:3 ω3 (ALA), 20:3 ω6 (DGLA), 20:4 
ω6 (ARA), 20:5 ω3 (EPA), 22:5 ω3 (DPA), 22:6 ω3 (DHA) 
Tab. 2: Biochemical measurements (TFA, TG, TC, LDL, HDL, CRP, HbA1c), 
Antioxidant indexes (SOD, GPX and CAT activities, and ORAC), and FAD activity 
measurements obtained from the supplemented groups with different fish oils diets 
(EPA:DHA 1:1, 2:1 and 1:2), linseed oil or soybean oil. Values are shown as means ± 
SD. Values with different superscript letters in the same row indicate significant 
difference at p < 0.05 between dietary groups. 
Tab. 3: Levels of lipid mediators in plasma derived from ARA, EPA and DHA 
obtained from the dietary interventions. Results are expressed as as ng/mL for derived 
eicosanoids and docosanoids, and µg/mL for PUFAs. Values are shown as means ± SD. 
For the ANOVA analysis, data from 1:2 diet have not been considered for most of 
compounds due to the high variability observed. Values with different superscript letters 
in the same row indicate significant difference at p < 0.05 between dietary groups. 
Tab. 4: Correlation Pearson indexes between lipid mediator levels in plasma and the 
weekly dietary dose of ARA, EPA and DHA. 
 
Figure captions: 
Fig.1: Cascade of formation to ARA, EPA and DHA oxidized derived compounds from 
enzymatic and non enzymatic pathways [8,45]. 
 
Supplementary electronic material captions: 
S1: Fatty acid composition of soybean oil, linseed oil and fish oil mixtures (EPA:DHA 
1:1, 2:1 and 1:2) supplemented to Wistar rats. Results are expressed as a percentage of 
total fatty acids (mg/100mg of Total FA). Weekly dose of EPA, DHA, ALA, ARA and 
LA expressed as mg/kg rat. Values are shown as means ± SD. 16:0 (palmitic acid), 16:1 
ω7 (palmitoleic acid, PA), 18:0 (stearic acid), 18:1 ω9 (oleic acid, OA), 18:1 ω7 
(vaccenic acid), 18:2 ω6 (LA), 18:3 ω3 (ALA), 20:3 ω6 (DGLA), 20:4 ω6 (ARA), 20:5 
ω3 (EPA), 22:5 ω3 (DPA), 22:6 ω3 (DHA) 
S2: Retention times, collision energies and MS/MS transitions for ESI-LC-LIT/MS/MS 
S3: Comparison of the plasma FFA profile from Wistar rats supplemented with 
different fish oils diets (EPA:DHA 1:1, 2:1 and 1:2), linseed oil or soybean oil. Results 
are expressed as percentage of total fatty acids (mg/100mg) 
S4: Comparison of the FA erythrocyte membrane profile from Wistar rats supplemented 
with different fish oils diets (EPA:DHA 1:1, 2:1 and 1:2), linseed oil or soybean oil. 
Results are expressed as percentage of total fatty acids (mg/100mg) 
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Table 1  
 
  
RATIO 1:1 
(EPA:DHA) 
RATIO 2:1 
(EPA:DHA)  
RATIO 1:2 
(EPA:DHA)  
 
Soybean 
 
Linseed 
  
FFA 
(Plasma) 
FA 
(EM) 
FFA 
(Plasma) 
FA 
(EM) 
FFA 
(Plasma) 
FA 
(EM) 
FFA 
(Plasma) 
FA 
(EM) 
FFA 
(Plasma) 
FA 
(EM) 
 FA MEAN SD MEAN SD MEAN SD MEAN SD MEAN SD MEAN SD MEAN SD MEAN SD MEAN SD MEAN SD 
16:0 (palmitic) 32.72a 1.1 22.61a 1.5 31.69a 1.4 22.55a 0.6 31.63a 1.1 22.58a 0.7 32.12a 0.8 22.48a 0.8 31.03a 1.1 23.76a 2 
16:1 7 (PA) 5.27ab 0.8 0.53a 0.1 5.43ab 0.6 0.50a 0.04 5.26ab 0.6 0.60a 0.1 6.09a 0.5 0.63a 0.1 4.86b 0.6 0.56a 0.1 
18:0 (stearic) 10.71a 2.5 14.09a 1.5 9.51a 3.5 15.09a 0.8 8.86a 1.2 15.22a 0.7 9.12a 0.6 14.60a 0.3 8.73a 1.2 12.83a 2.2 
18:1 9 (OA) 21.54a 0.9 6.55a 0.6 21.37a 1.5 6.12a 0.2 22.89a 1.2 6.80a 0.8 22.89a 1.4 6.62a 0.4 23.84a 1.3 6.82a 0.5 
18:1 7 (vaccenic) 2.45a 0.2 2.28a 0.1 2.37a 0.3 2.22a 0.2 2.76a 0.3 2.23a 0.1 2.78a 0.1 2.51a 0.1 2.56a 0.2 2.32a 0.1 
18:2 6 (LA) 17.31a 1.9 7.63a 0.7 17.50a 2.2 7.64a 0.3 17.72a 1.7 7.44a 0.7 17.31a 1 6.95a 0.3 18.11a 1.3 7.45a 0.6 
18:33 (ALA) 0.94a 0.4 n.d. n.d.  1.01a 0.1 n.d.  n.d.  0.84a 0.4 n.d.  n.d.  0.96a 0.04 n.d  n.d  1.73a 0.3 n.d   n.d   
20:3 6 (DGLA)  n.d. n.d.  0.51a 0.03 n.d.  n.d.  0.53a 0.04 n.d.  n.d.  0.53a 0.1  n.d  n.d 0.47a 0.01 n.d   n.d   0.51a 0.04 
20:4 6 (ARA) 4.10a 0.1 21.51ab 1.3 4.55a 0.7 21.63ab 1.3 4.29a 1.1 21.42a 0.8 4.61a 0.7 23.32b 0.9 4.50a 1 22.72ab 1 
20:5 3 (EPA) 0.49a 0.1 1.03a 0.2 0.66a 0.2 1.09a 0.2 0.44a 0.1 0.89a 0.1 0.20b 0.02 0.56b 0.1 0.36a 0.1 0.82a 0.1 
22:5 3 (DPA) 0.67a 0.2 2.77a 0.2 0.83a 0.3 3.02a 0.2 0.76a 0.2 2.53a 0.1 0.31a 0.2 2.09a 0.1 0.76a 0.2 2.73a 0.2 
22:6 3 (DHA) 2.06a 0.3 7.11a 0.8 2.83a 0.7 6.82a 0.5 2.54a 0.4 6.92a 0.4 1.36b 0.2 5.70b 0.2 1.84ab 0.3 5.84b 0.5 
∑ 3 4.16a 0.3 10.91a 0.4 5.33b 0.3 10.94a 0.3 4.58a 0.3 10.34a 0.2 2.83c 0.1 8.35b 0.1 4.69a 0.2 9.39c 0.3 
∑ 6 21.41a 1 29.64ab 0.7 22.05a 1.4 29.79ab 0.5 22.01a 1.4 29.39a 0.5 21.92a 0.9 30.74b 0.4 22.61a 1.2 30.68b 0.5 
∑ SFA 43.43a 1.8 36.69a 1.5 41.20a 2.5 37.64a 0.7 40.49a 1.2 37.80a 0.7 41.24a 0.7 37.08a 0.5 39.76a 1.1 36.60a 2.1 
∑ MUFA 29.26a 0.7 9.37a 0.3 29.17a 0.8 8.84b 0.1 30.91b 0.7 9.63a 0.3 31.76b 0.7 9.76a 0.2 31.26b 0.7 9.70a 0.2 
∑ PUFA 25.57a 0.5 40.56ab 0.5 27.38b 0.7 40.73b 0.4 26.59ab 0.7 39.73a 0.4 24.75a 0.4 39.09a 0.3 27.30b 0.5 40.07ab 0.4 
6/3 5.15 2.72 4.14 2.72 4.81 2.84 7.75 3.68 4.82 3.27 
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Table 2 
 
Group 
RATIO 1:1 
(EPA:DHA) 
RATIO 2:1 
(EPA:DHA) 
RATIO 1:2 
(EPA:DHA) Soybean Linseed 
Biochemical measurements MEAN SD MEAN SD MEAN SD MEAN SD MEAN SD 
TFA (mg/dL) 267.7ab 38.4 233.8a 24.2 280.8ab 30.3 355.6c 87.7 316.9abc 61 
TG (mg/dL) 93.8a 67.8 64a 23.4 83.1a 10.4 108.5a 51.9 73.5a 25.2 
TC (mg/dL) 102a 26.5 98a 14.8 112.3a 20.8 125.8a 16.5 133.4a 41.2 
LDL (mg/dL) 8.6a 3.3 7.4a 0.8 8.3a 1.3 10.4a 2.2 10.1a 7.1 
HDL (mg/dL) 41.2a 11.1 42.3a 7.9 47.3a 8.1 51.3a 7.8 49.7a 9.1 
HDL/LDL 4.8a 5.7b 5.7b 4.9a 4.9a 
CRP (ug/mL) 147a 20.5 147.1a 22.4 140.1a 52.7 172.9a 38.2 142.9a 52 
HbA1c (%) 4.1a 0.2 4.4a 0.7 4.17a 0.3 6.4b 1 6.3b 1.8 
        Antioxidant indexes 
ORAC (mg/dL) 48.2a 16.9 23.6b 6 26.4b 9 30.3b 9.6 24.7b 9.7 
SOD (U/gHb) 2129.2a 586.5 1880.9ab 341.2 1226.1b 517.4 1443.8ab 426.2 1230.6 283.9b 
GPX (U/gHb) 107.1a 15 116.7b 30.7 67.7c 34.5 101.5abc 38.2 71.1c 9.6 
CAT (mmol/min/gHb) 57.4a 11.1 76.7a 28.2 61.4a 13.2 41.5a 34.6 37.2a 20.9 
              FAD activity 
SCD-16 [palmitoleic/palmitic] 0.1 0.1 0.1 0.1 0.1 
SCD-18 [oleic/stearic] 0.9 0.9 0.8 0.9 1 
5D [ARA/DGLA] 48.4 49 45.7 68.1 48.4 
6D [DGLA/LA] 0.03 0.03 0.04 0.03 0.04 
5/6D [EPA/ALA] 3.6 4.4 4.2 2.6 2.5 
5D [DHA/DPA] 8.2 7.5 8.1 7.8 6.4 
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Table 3 
 
Group 
RATIO 1:1 
(EPA:DHA) 
RATIO 2:1 
(EPA:DHA) 
RATIO 1:2 
(EPA:DHA) 
Soybean 
 
Linseed 
 
 MEAN SD MEAN SD MEAN SD MEAN SD MEAN SD 
Eicosanoids from EPA (ng/mL) 
12HEPE 59a 46 65a 23 299 356 65a 40 250b 62 
15HEPE 3.3a 1.1 3.7a 1.3 6.2 3.7 3.2a 0.7 7.1b 1.3 
12HpEPE 387a 300 411a 279 1269b 524 640ab 376 1462b 1043 
15HpEPE 388a 128 403ab 164 898 574 691bc 280 968c 156 
TXB3 3.3
a 0.004 n.d. n.d. 4.4 1.0 3.5a 0.2 4.2b 0.3 
Docosanoids from DHA (ng/mL) 
17HDoHE 40a 20 41a 11 173 175 64a 56 134b 23 
17HpDoHE 1482a 691 1596a 700 1853a 553 2175a 475 2159a 927 
Eicosanoids from ARA (ng/ml) 
11HETE 3.9a 2.1 4.4ab 1.5 9.9 9.6 6.7b 2.2 13.6c 1.8 
PGE2 8.2
a 1.8 9.9a 1.4 40.1 42 18.7a 12.4 38.8b 8.7 
PUFA precursors (ng/uL) 
EPA 2.6a 1.4 2.5a 0.6 1.4b 0.8 1.1b 0.3 1.1b 0.3 
DHA 13.1a 5.9 12.6ab 3.9 9.2abc 3.5 7.4bc 2.8 6c 1.7 
ARA 48ab 8 51a 9 36b 12 43ab 11 37b 6 
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Table 4 
 
Compounds 
Weekely intake 
of EPA 
Weekely intake 
of DHA 
Weekely intake 
of ARA 
Correlation Pearson indexes (-1 to 1) 
12HEPE 0,1781 0,6898 0,1066 
15HEPE 0,0486 0,7375 -0,0169 
12HpEPE -0,9122 -0,7924 -0,9120 
15HpEPE -0,9621 -0,7272 -0,9609 
TXB3 0,5295 0,2605 0,4746 
17HDoHE -0,1928 0,4941 -0,2623 
17HpDoHE -0,8662 -0,6991 -0,8820 
11HETE -0,2209 0,3144 -0,2934 
PGE2 -0,4604 0,2172 -0,5247 
EPA 0,9417 0,4363 0,9639 
DHA 0,9519 0,5521 0,9683 
ARA 0,8803 0,2146 0,9121 
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Figure 1 
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S1 
 
 
RATIO 1:1 
(EPA:DHA)  
RATIO 2:1 
(EPA:DHA)  
RATIO 1:2 
(EPA:DHA)  SOYBEAN LINSEED 
FATTY ACID MEAN SD MEAN SD MEAN SD MEAN SD MEAN SD 
16:0 (palmitic) 10.15 0.2 9.09 0.03 10.98 0.1 17.78 0.1 5.73 0.03 
16:1 7 (PA) 4.99 0.04 4.57 0.02 5.39 0.03 0.90 0.03 0.11 0.01 
18:0 (stearic) 2.94 0.03 2.95 0 2.97 0.01 2.07 0.01 4.75 0.02 
18:1 9 (OA) 6.41 0.06 6.18 0 6.61 0.04 18.75 0.03 21.37 0.06 
18:1 7 (vaccenic) 1.91 0.03 1.93 0.02 1.95 0.02 1.52 0.02 1.11 0.01 
18:2 6 (LA) 0.65 0.01 0.61 0 0.65 0.02 47.55 0.01 16.76 0.03 
20:0 0.32 0.01 0.39 0.01 0.20 0 0.00 0 0.00 0 
18:33 (ALA) 0.36 0.01 0.32 0 0.33 0.02 4.00 0.04 50.02 0.1 
20:1 9 0.98 0.03 1.39 0.01 0.63 0.02 1.43 0.09 n.d. n.d. 
18:4 3 1.51 0.02 1.56 0.02 1.64 0 0.15 0 n.d. n.d. 
20:2 6 0.21 0 0.28 0.01 0.17 0.01 0.20 0.05 n.d. n.d. 
20:3 6 (DGLA) 0.22 0.01 0.27 0.01 0.15 0 0.00 0 n.d. n.d. 
20:4 6 (ARA) 1.68 0.04 1.98 0.03 1.16 0.02 0.40 0.02 n.d. n.d. 
22:1 11 1.14 0.01 1.58 0.02 0.45 0.01 1.08 0 n.d. n.d. 
22:1 9 0.28 0.03 0.37 0.03 0.19 0.02 0.25 0.02 n.d. n.d. 
20:4 3 1.02 0.02 1.31 0.02 0.75 0.01 0.20 0.03 n.d. n.d. 
20:5 3 (EPA) 25.09 0.1 32.43 0.06 17.33 0.03 0.70 0.02 n.d. n.d. 
24:1 9 0.38 0 0.55 0.02 0.25 0.01 0.28 0.05 n.d. n.d. 
22:5 3 (DPA) 4.30 0.05 5.24 0.02 2.60 0.1 0.26 0.01 n.d. n.d. 
22:6 3 (DHA) 25.70 0.2 17.98 0.03 34.85 0.1 1.15 0.03 n.d. n.d. 
Total 3 PUFA 57.97 0.07 58.84 0.03 57.51 0.05 6.47 0.02 50.02 0.1 
Total 6 PUFA 2.76 0.01 3.14 0.01 2.14 0.01 48.15 0.02 16.76 0.03 
Total SFA 18.52 0.2 17.05 0.02 19.68 0.1 21.17 0.1 10.63 0.06 
Total MUFA 17.22 0.1 17.14 0.07 17.43 0.1 24.21 0.1 22.59 0.06 
Total PUFA 64.26 0.3 65.81 0.08 62.90 0.2 54.62 0.03 66.78 0.1 
weekly dose of EPA  159.30 205.84  110.03  4.45   
weekly dose of DHA  163.12 114.15  221.24  7.31   
weekly dose of ARA  10.65 12.55  7.37  2.54   
weekly dose of ALA  2.29 2.06  2.09  25.39  317.56 
weekly dose of LA 4.13 3.88  4.15  301.86  106.39  
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S2 
 
Compound Retention Time 
(min) 
LIT parameters 
Collision energy (eV) Quantification transition (m/z) 
8iso-PGF3α 6.79 30 351>253 
TXB3 6.97 19 367>195 
PGD3/PGE3 7.67 19 349>313 
8iso-PGF2α 8.28 28 353>299 
PGE2 9.09 20 351>315 
RvD1 9.80 25 375>141 
PDx 12.89 30 359>153 
LTB4 13.79 27 335>195 
15HpEPE 17.36 20 333>315 
12HpEPE 17.80 25 333>315 
15HEPE 17.92 27 317>219 
12HEPE 18.72 27 317>179 
5HEPE 20.47 25 317>255 
17HpDoHE 21.90 26 359>341 
17HDoHE 21.94 27 343>245 
11HETE 22.09 30 319>167 
12HETEd8 22.66 30 325>307 
11HDoHE 23.20 27 343>149 
4HDoHE 23.64 27 343>281 
EPA 24.43 27 301>257 
DHA 24.93 30 327>283 
ARA 25.10 30 303>259 
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